Journal of cardiology最新文献

{"title":"Impact of preoperative beta-hydroxy-beta-methylbutyrate, arginine, and glutamine supplementation on inflammation in patients with cardiac surgery: A secondary analysis of a randomized controlled trial","authors":"Masato Ogawa PT, PhD ,&nbsp;Seimi Satomi-Kobayashi MD, PhD ,&nbsp;Naofumi Yoshida MD, PhD ,&nbsp;Kodai Komaki PT ,&nbsp;Takumi Hirabayashi PT, PhD ,&nbsp;Kumiko Wakida RD ,&nbsp;Saori Saitoh RD ,&nbsp;Takeshi Inoue MD ,&nbsp;Tomoya Yamashita MD, PhD ,&nbsp;Yoshitada Sakai MD, PhD ,&nbsp;Michiko Takahashi MD, PhD ,&nbsp;Ken-ichi Hirata MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.08.017","DOIUrl":"10.1016/j.jjcc.2025.08.017","url":null,"abstract":"<div><h3>Background</h3><div>Preoperative physical frailty is a significant predictor of adverse postoperative outcomes in older patients undergoing cardiac surgery. Inflammation plays a crucial role in the development of frailty and contributes to postoperative complications. This study investigated the effects of preoperative beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine supplementation on inflammatory markers, nutritional status, and renal function in older patients undergoing cardiac surgery.</div></div><div><h3>Methods</h3><div>This was a secondary analysis of a single-center, open-label, randomized controlled trial. Patients aged ≥65 years scheduled for elective cardiac surgery were randomized to receive either HMB supplementation (1200 mg HMB, 7000 mg <span>l</span>-glutamine, and 7000 mg L-arginine, twice daily) or routine care for at least two weeks before surgery. Serum levels of tumor necrosis factor-alpha (TNF-α), and other biochemical markers were measured at baseline, pre-surgery, and two weeks post-surgery.</div></div><div><h3>Results</h3><div>Forty-four patients (mean age 72.5 years, 36 % women) were analyzed. Preoperative HMB supplementation significantly reduced pre-surgery serum TNF-α levels compared to the control group (0.85 ± 0.28 pg/mL vs. 1.10 ± 0.44 pg/mL, <em>p</em> = 0.039). However, this difference was not observed two weeks post-surgery. No significant differences were observed in C-reactive protein levels or other nutritional markers between the two groups at any time point.</div></div><div><h3>Conclusions</h3><div>Preoperative supplementation with a combination of HMB, glutamine, and arginine was effective in reducing preoperative TNF-α levels in older patients undergoing cardiac surgery, suggesting a potential anti-inflammatory effect. This anti-inflammatory effect suggests a potential mechanism for improving postoperative outcomes and warrants further investigation.</div><div><strong>Registration number of Clinical Trial:</strong> UMIN000030490 (<span><span>https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034773</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 561-567"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of mitral valve tethering caused by apical sparing contractility pattern in transthyretin amyloid cardiomyopathy","authors":"Keitaro Shinada MD ,&nbsp;Jin Endo MD, PhD ,&nbsp;Hikaru Tsuruta MD, PhD ,&nbsp;Akito Matsumura MD ,&nbsp;Kohsuke Shirakawa MD, PhD ,&nbsp;Marina Okada MD, PhD ,&nbsp;Hidehiko Ikura MD ,&nbsp;Hiroki Kitakata MD, PhD ,&nbsp;Hidenori Moriyama MD, PhD ,&nbsp;Masaki Ieda MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.08.005","DOIUrl":"10.1016/j.jjcc.2025.08.005","url":null,"abstract":"<div><h3>Background</h3><div>In transthyretin amyloid cardiomyopathy (ATTR-CM), pathological changes occur in the mitral valve, but the mechanism remains largely unknown. This study aimed to clarify the mechanism through quantitative analysis of the morphology and function of the mitral valve using three-dimensional (3D) echocardiography.</div></div><div><h3>Methods</h3><div>A total of 69 patients with ATTR-CM who underwent 3D transthoracic echocardiography from December 2015 to October 2022 were compared with 30 healthy controls.</div></div><div><h3>Results</h3><div>3D echocardiographic analysis revealed increased mitral annular dilation and mitral valve tethering in patients with ATTR-CM. In the preserved left ventricular ejection fraction (ATTR-pEF) subgroup (<em>n</em> = 36), mitral valve tethering was more pronounced, despite normal mitral annular area. The rate of change in the distance between mitral annulus and papillary muscle was significantly higher in ATTR-CM patients and was an independent predictor of mitral valve tethering in the ATTR-pEF group. Among indices of left ventricular function, only the apical sparing ratio was correlated with this change ratio in the multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Mitral valve tethering is observed in ATTR-CM regardless of EF. Apical sparing at systole increases in the mitral annulus-papillary muscle distance, leading to mitral valve tethering.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 552-560"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist in patients with left ventricular thrombus: A meta-analysis of randomized controlled trials","authors":"Tadashi Asanuma ,&nbsp;Yuriko Hiruma (MD) ,&nbsp;Atsuyuki Watanabe (MD) ,&nbsp;Tomonari M. Shimoda (MD) ,&nbsp;Masao Iwagami (MD, PhD) ,&nbsp;Kaveh Hosseini (MD) ,&nbsp;Leandro Slipczuk (MD, PhD) ,&nbsp;Jose Wiley (MD, MPH) ,&nbsp;Alexandros Briasoulis (MD, PhD) ,&nbsp;Hisato Takagi (MD, PhD) ,&nbsp;Tadao Aikawa (MD, PhD) ,&nbsp;Toshiki Kuno (MD, PhD)","doi":"10.1016/j.jjcc.2025.09.012","DOIUrl":"10.1016/j.jjcc.2025.09.012","url":null,"abstract":"<div><h3>Background</h3><div>While vitamin K antagonist (VKA) has traditionally been the preferred treatment for left ventricle (LV) thrombus, the comparative efficacy and safety of direct oral anticoagulants (DOACs) with VKA in this setting remain unelucidated.</div></div><div><h3>Methods</h3><div>A comprehensive literature search of PubMed and Google Scholar was conducted through May 7, 2025, to identify randomized controlled trials (RCTs) comparing DOACs with VKA in patients with LV thrombus. The primary endpoint was complete resolution of LV thrombus. Secondary endpoints included stroke, systemic embolism, the composite of both stroke and systemic embolism, major bleeding, and all-cause mortality. Both pairwise and network meta-analyses were performed using a random-effects model to synthesize the effect estimates.</div></div><div><h3>Results</h3><div>Eight RCTs comprising a total of 576 patients were included. Collectively, 88.9 % of the patients treated with DOACs and 81.7 % of those receiving VKA experienced LV thrombus resolution, with a synthesized risk ratio (RR) of 1.01 [95 % confidence interval (CI), 0.94 to 1.07]. No significant differences were observed between the two groups for stroke (RR, 0.75; 95 % CI, 0.25 to 2.19), systemic embolism (RR, 0.21; 95 % CI, 0.01 to 4.58), the composite of stroke and systemic embolism (RR, 0.64; 95 % CI, 0.17 to 2.32), major bleeding (RR, 0.43; 95 % CI, 0.16 to 1.19), or all-cause mortality (RR, 0.92; 95 % CI, 0.36 to 2.31). A network meta-analysis showed no statistically significant differences across the anticoagulants in any clinical endpoint.</div></div><div><h3>Conclusion</h3><div>DOACs showed comparable efficacy and safety to VKA in managing LV thrombus, supporting their potential role as a viable alternative anticoagulation strategy.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 618-621"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker-based pre-heart failure screening in a middle-aged rural population","authors":"Yuichiro Mori MD, MPH ,&nbsp;Shunsuke Natori MD, PhD ,&nbsp;Toshio Arai MD, PhD ,&nbsp;Fujio Kakuya MD, PhD ,&nbsp;Shingo Fukuma MD, PhD","doi":"10.1016/j.jjcc.2025.08.019","DOIUrl":"10.1016/j.jjcc.2025.08.019","url":null,"abstract":"<div><h3>Background</h3><div>Guidelines recommend biomarker-based screening for pre-heart failure (pre-HF) among at-risk populations. Although the asymptomatic nature of pre-HF necessitates proactive screening, real-world implementation remains understudied. This retrospective study analyzed data from a regional pre-HF screening initiative, integrated into annual health screenings, to evaluate: (1) the prevalence of elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, (2) associated echocardiographic findings, and (3) adherence across the screening-to-consultation pathway.</div></div><div><h3>Methods</h3><div>This study included individuals aged 40–74 years who received pre-HF screening in Furano City, Japan, from October 2023 to March 2024. During the study period, NT-proBNP testing was incorporated into an existing annual health screening program. Participants with elevated NT-proBNP levels (≥125 pg/mL) were referred for cardiology consultation and echocardiography.</div></div><div><h3>Results</h3><div>Among 1585 screening attendees (mean age, 54.5 years; females, 57.0 %), 1579 (99.6 %) underwent NT-proBNP testing. Elevated levels were found in 118 (7.5 %) individuals. These individuals were older, female, and had a higher blood pressure. Of these 118 individuals, only 55 (46.6 %) attended the follow-up cardiology consultation. Among those evaluated with echocardiography, 22 (40.0 %) had abnormal findings (increased left atrial volume index and left ventricular end-diastolic volume index being the most common).</div></div><div><h3>Conclusions</h3><div>Integrating NT-proBNP testing into a public health screening program achieved near-perfect testing adherence. The program identified 7.5 % of the general middle-aged population as having pre-HF with predominantly benign echocardiographic changes, highlighting important prevention opportunities. However, a critical drop-off in adherence to specialist consultation highlights a major implementation gap. Optimizing the post-screening pathway is essential to maximize the potential benefits of population-wide pre-HF screening.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 568-575"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daprodustat for patients with heart failure and renal anemia: A pilot multicenter, open-label, randomized controlled study","authors":"Yu Suresvar Singh MD ,&nbsp;Yuya Matsue MD, PhD ,&nbsp;Takashi Iso MD, PhD ,&nbsp;Yudai Fujimoto MD ,&nbsp;Naotake Yanagisawa PhD ,&nbsp;Jun Shitara MD, PhD ,&nbsp;Satoru Suwa MD ,&nbsp;Shota Miyakuni MD, PhD ,&nbsp;Akira Mizukami MD ,&nbsp;Yuki Saito MD, PhD, FJCC ,&nbsp;Yasuo Okumura MD, PhD, FJCC ,&nbsp;Kiyoshi Takasu MD, PhD ,&nbsp;Takashi Tokano MD, PhD ,&nbsp;Masaru Hiki MD, PhD ,&nbsp;Kikuo Isoda MD, PhD, FJCC ,&nbsp;Tadashi Miyazaki MD, PhD ,&nbsp;Katsumi Miyauchi MD, PhD, FJCC ,&nbsp;Tohru Minamino MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.09.011","DOIUrl":"10.1016/j.jjcc.2025.09.011","url":null,"abstract":"<div><h3>Background</h3><div>Anemia and renal failure, common comorbidities in patients with heart failure (HF), are associated with increased mortality. Hypoxia-inducible factor prolyl hydroxylase inhibitors, such as daprodustat, treat renal anemia by stimulating erythropoiesis and enhancing iron availability. However, its efficacy in treating HF with renal anemia remains to be determined.</div></div><div><h3>Methods</h3><div>This pilot, multicenter, open-label, randomized controlled trial was conducted in five hospitals in Japan. Patients with HF, anemia (hemoglobin, 7.5–11 g/dL), and renal impairment (estimated glomerular filtration rate, &lt;60 mL/min/1.73 m²) not requiring hemodialysis were randomized 1:1 to receive daprodustat or standard of care. The primary endpoint was the hemoglobin level at 16 weeks. The secondary endpoints included blood transfusion rates, alleviation of HF symptoms, changes in N-terminal pro-B-type natriuretic peptide and iron-related biomarkers, and cardiac structural and functional changes.</div></div><div><h3>Results</h3><div>Twenty-one patients were randomized between March 2022 and November 2023. At 16 weeks, the mean hemoglobin level was significantly higher in the daprodustat group (12.1 ± 0.73 g/dL) than in the standard of care group (10.3 ± 0.97 g/dL, <em>p</em> &lt; 0.001). Serum iron, ferritin, hepcidin, and transferrin saturation levels were significantly lower, whereas N-terminal pro-B-type natriuretic peptide levels were significantly higher in the daprodustat treatment group. Kansas City Cardiomyopathy Questionnaire Total Symptom Score improvement (44.4 % vs. 55.6 %, <em>p</em> = 0.99) and structural and functional cardiac parameters showed no significant differences.</div></div><div><h3>Conclusions</h3><div>Daprodustat effectively increases hemoglobin levels and modifies iron metabolism by decreasing hepcidin levels and increasing iron utilization in patients with HF and renal anemia.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 592-598"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of night-time onset on neurologically favourable survival between patients with and without bystander cardiopulmonary resuscitation","authors":"Kazuya Tateishi MD ,&nbsp;Yuichi Saito MD ,&nbsp;Yuki Shiko PhD ,&nbsp;Kohei Takahashi MS ,&nbsp;Hideki Kitahara MD ,&nbsp;Yoshio Kobayashi MD, PhD, FJCC ,&nbsp;Naohiro Yonemoto MPH, PhD ,&nbsp;Tetsuya Matoba MD, PhD ,&nbsp;Yoshio Tahara MD, PhD ,&nbsp;Japanese Circulation Society Resuscitation Science Study (JCS-ReSS) Group","doi":"10.1016/j.jjcc.2025.09.015","DOIUrl":"10.1016/j.jjcc.2025.09.015","url":null,"abstract":"<div><h3>Background</h3><div>Patients with out-of-hospital cardiac arrest (OHCA) during the night tend to have worse outcomes than those with OHCA during the day. One possible explanation for poorer outcomes in patients with night-time onset is the lower quality of bystander cardiopulmonary resuscitation (CPR), although the exact cause has not been fully clarified. This study evaluated the differences between day and night-time-OHCA onset on neurologically favourable survival for patients with and without bystander CPR.</div></div><div><h3>Methods</h3><div>A cohort of 118,822 patients with witnessed OHCA and prehospital return of spontaneous circulation was obtained from a nationwide OHCA registry database in Japan. The primary endpoint was neurologically favourable survival at 1 month. We also investigated the impact of night-time bystander CPR presence or absence as a sub-analysis.</div></div><div><h3>Results</h3><div>The neurologically favourable survival rate was significantly lower for patients with night-time than those with daytime OHCA onset (30.7 % vs. 31.8 %, <em>p</em> &lt; 0.001). The multivariable analysis determined night-time OHCA onset was a significant negative factor associated with neurologically favourable survival at 1-month [odds ratio (OR) 0.95; 95 % confidence interval (CI) 0.92–0.98, <em>p</em> = 0.002]. This negative effect of night-time onset compared to daytime was more pronounced for patients with bystander CPR from a citizen (OR 0.91; 95 % CI 0.87–0.95, <em>p</em> &lt; 0.001). In contrast, this negative effect was attenuated in patients without bystander CPR (OR 1.00; 95 % CI 0.95–1.04, <em>p</em> = 0.836).</div></div><div><h3>Conclusion</h3><div>These results suggest that the insufficient quality of bystander CPR may be one of the causes for the negative impact of night-time OHCA compared to daytime on patients.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 586-591"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of pre-implantation hyponatremia in pacemaker recipients: A population-based study","authors":"Yuval Avidan MD ,&nbsp;Dana Hadar ,&nbsp;Hila Cohen ,&nbsp;Jihad Ali MD ,&nbsp;Amir Yahav MD, PhD ,&nbsp;Asaf Danon MD, MSc ,&nbsp;Sameer Kassem MD, PhD ,&nbsp;Amir Aker MD","doi":"10.1016/j.jjcc.2025.09.016","DOIUrl":"10.1016/j.jjcc.2025.09.016","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 622-624"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply","authors":"Yuki Matsuoka MD ,&nbsp;Yohei Sotomi MD, PhD ,&nbsp;Yasushi Sakata MD, PhD","doi":"10.1016/j.jjcc.2025.06.017","DOIUrl":"10.1016/j.jjcc.2025.06.017","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 625-626"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase angle as a predictor of congestion, muscle wasting, and malnutrition in cardiovascular surgery patients","authors":"Ikuko Shibasaki MD, PhD ,&nbsp;Taira Fukuda MD, PhD ,&nbsp;Suguru Hirose MD, PhD ,&nbsp;Yusuke Takei MD, PhD ,&nbsp;Shigeru Toyoda MD, PhD, FJCC ,&nbsp;Hirotsugu Fukuda MD, PhD, FJCC ,&nbsp;Toshiaki Nakajima MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.09.004","DOIUrl":"10.1016/j.jjcc.2025.09.004","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 612-614"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perceptions on cardiac rehabilitation participation following hospitalization for acute coronary syndrome","authors":"Momoko Masuda (PT) ,&nbsp;Kazuki Tobita (PT) ,&nbsp;Ayumi Goda (MD) ,&nbsp;Daisuke Fujisawa (MD) ,&nbsp;Ryo Nakamaru (MD) ,&nbsp;Shinsuke Takeuchi (MD) ,&nbsp;Kohei Koyama (MD) ,&nbsp;Syoichi Tashiro (MD) ,&nbsp;Shin Yamada (MD) ,&nbsp;Kyoko Soejima (MD) ,&nbsp;Takashi Kohno (MD, FJCC)","doi":"10.1016/j.jjcc.2025.09.014","DOIUrl":"10.1016/j.jjcc.2025.09.014","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"86 6","pages":"Pages 615-617"},"PeriodicalIF":2.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}